CRISPR Therapeutics announced that its senior management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on November 17, 2026. The event will be webcast live and archived for 14 days on the company's website. CRISPR Therapeutics is a leading biopharmaceutical company known for pioneering CRISPR/Cas9 gene editing and recently achieved a milestone with the approval of the first CRISPR-based therapy for sickle cell disease and beta thalassemia. The presentation highlights the company's ongoing innovation and strategic collaborations in gene editing and biopharmaceutical development.
As of Nov 10, 2026 20:43 WIB, CRISPR Therapeutics (CRSP) shares trade at USD 49.70 on Pluang, down 0.68% in the past day. The stock shows strong investor interest with 100% buy order activity and a typical hold time of 79 days. The company's market capitalization stands at $4.85 billion, highlighting its significant presence in the health sector.
CRISPR Therapeutics presented Phase 1b data showing that a single treatment with CTX310, a gene editing therapy, reduced ANGPTL3 protein by 65% and triglycerides by 63% at 30 days in patients with severe hypertriglyceridemia. The treatment was well t...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
